|
|
Mckesson Corporation (MCK) |
|
Price: $438.6600
$0.42 
0.096%
|
| Day's High:
| $441.21
| Week Perf:
| 2.66 %
|
| Day's Low: |
$ 435.91 |
30 Day Perf: |
4.12 % |
| Volume (M): |
962 |
52 Wk High: |
$ 444.80 |
| Volume (M$): |
$ 421,772 |
52 Wk Avg: |
$383.14 |
| Open: |
$437.02 |
52 Wk Low: |
$331.75 |
|
|
| Market Capitalization (Millions $) |
59,921 |
| Shares
Outstanding (Millions) |
137 |
| Employees |
75,000 |
| Revenues (TTM) (Millions $) |
284,040 |
| Net Income (TTM) (Millions $) |
3,910 |
| Cash Flow (TTM) (Millions $) |
297 |
| Capital Exp. (TTM) (Millions $) |
582 |
Mckesson Corporation
McKesson Corporation, is a Fortune 16 corporation providing supply, information
and care management products and services designed to reduce costs and improve
quality across the healthcare industry.
We conduct our business through three segments. Through our Pharmaceutical
Solutions segment, we are a leading distributor of ethical and proprietary drugs,
and health and beauty care products throughout North America.
Company Address: 6555 State Hwy 161 Irving 75039 TX
Company Phone Number: 446-4800 Stock Exchange / Ticker: NYSE MCK
| MCK is expected to report next financial results on October 31, 2023. |
Next quarterly dividend pay out on October 02, 2023. |
|
|
|
Customers Net Income fell by |
MCK's Customers Net Profit Margin fell to |
-20.54 % |
2.22 %
|
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
|
Can B Corp
By
As a seasoned investor, I analyze financial reports rigorously, looking for patterns and insights that would aid in making informed decisions. This article aims to interpret the latest financial results of Can B Corp, shedding light on its dwindling performance and the subsequent impact on its share prices.
The financial interval ending June 30, 2023, reveals a concerning loss for Can B Corp. The company reported a loss of $-0.37 per share, showing a slight improvement over the previous year's loss of $-0.49 per share. However, it is a decline from the previous financial reporting period, where the loss stood at $-0.36 per share. Such losses illustrate the challenges faced by Can B Corp in the current market.
|
|
Stemtech Corporation
Stemtech Corporation, a company operating in the [relevant industry], has experienced significant fluctuations in its share prices over the last five trading days. With a downward trend of -7.21%, the company's shares now reflect a year-to-date performance decrease of -48.52%. These figures suggest a challenging period for Stemtech, raising questions about the future implications for the company.
1. Break-even in Q2 2023:
During the fiscal second quarter of 2023, Stemtech Corporation reached a break-even point of $0.00 per share, a significant improvement compared to the previous year's loss of $-0.56 per share. However, compared to the prior quarter's loss of $-0.04 per share, there seems to be a minimal improvement. This break-even situation indicates that Stemtech is making efforts to improve its financial performance.
|
|
Trxade Health Inc
Trxade Health Inc, a healthcare services company that operates an online marketplace for pharmaceuticals, recently released its second-quarter 2023 financial report. Unfortunately, the report shows a weak business performance, resulting in a significant increase in losses compared to the same period last year.
One of the key metrics that highlights this decline is the net loss per share, which surged to $-2.90 from $-0.13. This indicates a substantial decrease in profitability for the company. Additionally, the revenue for the second quarter fell by 29.009% to $2.25 million, compared to $3.17 million in the previous year. This decline in revenue further emphasizes the challenges faced by Trxade Health Inc during this period.
|
|
Bimi International Medical Inc
BIMI Reports Disappointing Financial Results for Q1 2023: Future Performance Remains Uncertain
Bimi International Medical Inc (BIMI) recently disclosed its financial results for the interval ending March 31, 2023, which painted a disappointing picture for the company. Revenue experienced a significant decline of -36.299% to $3.20 million, while net loss per share reached $-0.23, as compared to $-0.27 in the first quarter of 2022.
This downturn stands in contrast to the remainder of the Pharmacy Services and Retail Drugstore sector, which saw a revenue improvement in the first quarter of 2023. In the previous reporting season, BIMI's EPS fell from $6.39 per share, while revenue turned positive from $-34,046.66 million.
|
|
Sharing Services Global Corporation
Sharing Services Global Corporation (SHRV) recently released its first quarter financial report for 2024, which highlighted concerning figures in terms of revenue and net loss per share. However, it is important to compare these figures with previous periods and industry peers to gain a more comprehensive understanding of the company's situation. This article will examine the implications of SHRV's financial results and discuss how they may impact the company moving forward.
1. Revenue Meltdown and Net Loss Per Share:
SHRV's first quarter of 2024 saw revenue decline by a significant -45.733% to $2.88 million. Simultaneously, the net loss per share remained stagnant at $-0.01, which was identical to the previous financial period ending in June 2022. These figures indicate a worrying trend and pose a challenge for SHRV to reverse the declining revenue and bring about profitability.
|
| Per Share |
Current |
| Earnings (TTM) |
26.84 $ |
| Revenues (TTM) |
2079.36 $
|
| Cash Flow (TTM) |
2.17 $ |
| Cash |
19.3 $
|
| Book Value |
-
|
| Dividend (TTM) |
2.09 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
26.84 $
|
| Revenues (TTM) |
2079.36 $ |
| Cash Flow (TTM) |
2.17 $ |
| Cash |
19.3 $
|
| Book Value |
- |
| Dividend (TTM) |
2.09 $ |
|
|
| |
| U.S. Healthcare direct distribution & services |
|
Segment |
|
 |
of total Revenue |
| Canada distribution & services |
|
Segment |
|
|
of total Revenue |
| Pharmaceutical Solutions |
|
Segment |
|
|
of total Revenue |
| Medical-Surgical Solutions |
|
Segment |
|
|
of total Revenue |
| |
|
|
1.24% 